The bill enacted as R.S. 37:23.5 establishes regulations concerning the provision and compounding of peptides by healthcare providers and pharmacists in Louisiana. It explicitly prohibits professional or occupational licensing boards from restricting healthcare providers with prescriptive authority from supplying patients with peptides sourced from either FDA-registered 503B outsourcing facilities or 503A compounding pharmacies, provided these entities comply with relevant federal regulations.

Additionally, the bill allows Louisiana licensed pharmacists in state-permitted pharmacies to compound and dispense peptides, as long as they adhere to the same federal compliance standards. This legislation aims to ensure that patients have access to peptide treatments while maintaining safety and regulatory compliance within the healthcare system.